Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions.
Abiraterone
De-novo mCSPC
De-novo metastatic castration sensitive prostate cancer
Local radiotherapy
Low-risk
Prognostic
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
23
01
2019
revised:
12
04
2019
accepted:
08
05
2019
pubmed:
22
5
2019
medline:
10
9
2019
entrez:
22
5
2019
Statut:
ppublish
Résumé
De-novo metastatic castration sensitive prostate cancer (mCSPC) is a subgroup of prostate cancer associated with poor prognosis. Recently, the treatment of mCSPC has been enriched by new life-prolonging options, including the combination of docetaxel or abiraterone acetate with androgen deprivation therapy (ADT). Of note, the advantage of chemohormonal therapy was more relevant in the subgroup of high-volume disease compared to low-volume, while the survival prolongation of abiraterone was observed only in high-risk patients. Choosing the most appropriate therapy is one of the most debated issues. This review describes the latest news on de-novo mCSPC to better outline patients' management. At the ESMO 2018 Congress two novel studies focused on this setting have been presented, trying to define the role of radiotherapy to the primary tumour and the efficacy of abiraterone acetate in the subset of low-risk patients. We have analysed these results in light of the evidence already available.
Identifiants
pubmed: 31112886
pii: S1040-8428(19)30091-5
doi: 10.1016/j.critrevonc.2019.05.005
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
83-86Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.